FindTrial
Sign In

Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01205009
Enrollment
100
Registered
2010-09-20
Start date
2011-04-30
Completion date
Unknown
Last updated
2011-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

in-vitro fertilization, poor responders, human chorionic gonadotropin, Fertility Agents, Female

Brief summary

In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.

Interventions

DRUGOvitrelle

One dose of Ovitrelle 250 mcg

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
40 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* women \>39 years on IVF treatment

Exclusion criteria

* polycystic ovary syndrome * Any allergy to injection of human chorionic gonadotropin before

Design outcomes

Primary

MeasureTime frame
number of oocytes retrieved1 month

Countries

Israel

Contacts

Primary ContactMushira Aboo Dia,, MD
mushiraa@gmail.com
Backup ContactHadas Lemberg, PhD
lhadas@hadassah.org.il00 972 2 6777572

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026